ArticleCancer chemotherapy and pharmacology2017

Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041).

Naoya Yamazaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.